Daxibotulinumtoxina Dosage

Medically reviewed by Drugs.com. Last updated on Sep 19, 2023.

Usual Adult Dose for Glabellar Lines

Inject 8 units (0.1 mL) intramuscularly into each of 5 sites (two injections in each corrugator muscle and one injection in the procerus muscle) for a total dose of 40 units

Comments:

• Refer to manufacturer information for specific administration instructions, including dilution, needle orientation, and injection site diagrams.
• The safety and effectiveness of dosing more frequently than every 3 months have not been clinically evaluated.

Use: For the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients

Usual Adult Dose for Cervical Dystonia

Inject 125 to 250 units intramuscularly as a divided dose among affected muscles

Comments:

• When selecting the first dose of this drug in patients who have previously been treated with another botulinum toxin, the prior dose, response to therapy, duration of effect, and adverse event history should be considered.
• Dysphagia may be reduced by limiting the dosage injected into the sternocleidomastoid muscle.
• Refer to manufacturer information for specific administration instructions, including dilution.

Use: For the treatment of cervical dystonia in adult patients

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Dose Adjustments

Potency units of this drug is specific to the preparation and assay method utilized. They are not interchangeable with other botulinum toxin preparations.

Precautions

US BOXED WARNING:
DISTANT SPREAD OF TOXIN EFFECT:

• The effects of all botulinum toxin products, including this drug, may spread from the area of injection to produce symptoms consistent with botulinum toxin effects.
• These symptoms have been reported hours to weeks after injection.
• Swallowing and breathing difficulties can be life-threatening and there have been reports of death.
• This drug is not approved for any condition other than glabellar lines and cervical dystonia.

CONTRAINDICATIONS:

• Hypersensitivity to any botulinum toxin preparation or any of the ingredients
• Infection at the injection site(s)

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:

• Indication specific dosage and administration recommendations should be followed.
• The safe and effective use depends upon proper storage, selection of the correct dose, and proper reconstitution and administration techniques. See manufacturer product labeling for indication specific administration recommendations, including preparation and dilution instructions.
• Dosing units of this drug are not interchangeable between commercial products.
• This drug is intended to be administered intramuscularly into affected muscles.
• Administer this drug within 72 hours after reconstitution.
• After reconstitution, use each vial for only one injection session and for only one patient.

Storage requirements:

• Unopened vials: Store at room temperature 20C to 25C (68F to 77F) or refrigerated at 2C to 8C (36F to 46F) in the original carton to protect from light.
• Reconstituted vials: Store refrigerated between 2C to 8C (36F to 46F) and protected from light for up to 72 hours.
• Do not freeze the reconstituted solution.

Reconstitution/preparation techniques:

• The manufacturer product information should be consulted.

Monitoring:
Musculoskeletal: Excessive muscle weakness; Muscle paralysis
Nervous system: Neuromuscular compromise
Monitor for distant spread of toxin.

Patient advice:

• Read the US FDA-approved patient labeling (Patient Information and Instructions for Use).
• Patients and caregivers should be instructed to inform their health care provider if they develop any unusual symptoms or if any existing symptoms worsen. They should be instructed to seek immediate medical attention if they have trouble swallowing, speaking, or breathing.
• Patients experiencing loss of strength, muscle weakness, blurred vision, dizziness, or drooping eyelids should avoid engaging in potentially hazardous activities, including driving.
• Patients should inform their physician if symptoms of eye dryness develop.

Frequently asked questions

• What is Daxxify, the recent FDA-alternative to Botox?

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer